Article

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.

2020-08-03

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Although weekly paclitaxel and trastuzumab is generally considered to be less cardiotoxic than an anthracycline regimen, low baseline left ventricular ejection fraction (LVEF) of ≤55%, hypertension, and high body mass index (BMI) have been reported as risk factors for cardiotoxicity. Without these risk factors, the incidence of cardiotoxicity is expected to be m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 119a4123-625c-5e7c-b851-345a2211c794
DOI: 10.21203/rs.3.rs-50661/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.DOI 10.21203/rs.3.rs-50661/v1Read

Prevalence and Effects of Late Cardiotoxicity induced by Anthracyclines and/or Anti- HER2 Antibodies in Patients with Breast Cancer: a real world studySemantic proximity Read

Post-chemotherapy Cardiotoxicity in Women With Breast CancerSemantic proximity Read

Risk of heart disease following breast cancer: results from a population-based cohort studySemantic proximity Read

Trastuzumab-induced cardiotoxicity: is it a personalized risk?Semantic proximity Read

Heart Failure in Relation to Anthracyclines and Other Chemotherapies.Semantic proximity Read

The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.Semantic proximity Read

Left Atrial Volume Index, Other Systolic and Diastolic Transthoracic Echocardiographic Parameters as Early Predictors for Asymptomatic Trastuzumab Target Cancer Therapy-Related Cardiac Dysfunction among HER2-Positive Breast Cancer Patients at a Tertiary Medical Center in Metro Manila – a Single-Center Prospective Cohort StudySemantic proximity Read

The incidence of adjuvant chemotherapy-related early-onset cardiac events in breast cancer patients and its relationship with genetic susceptibility: A prospective cohort studySemantic proximity Read

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trialSemantic proximity Read

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read

Clinical Impact of Interruption in Adjuvant Trastuzumab Therapy in Patients with Operable HER-2 Positive Breast CancerSemantic proximity Read